The Healthy Brain and Child Development National Consortium Administrative Core NIH U24DA055325Sep 30, 2021 - Jun 30, 2026 Role: Principal Investigator |
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses NIH P50HD106463Sep 10, 2021 - Jul 31, 2026 Role: Co-Principal Investigator |
Home vs. Clinic Collection of Human Milk in Evaluating the Pharmacokinetics of Four Medications NIH R21HD104412Nov 15, 2020 - Oct 31, 2022 Role: Principal Investigator |
Evaluating the Effects of COVID-19 Infection in Pregnancy and Lactation UC Office of the President R00RG2372Apr 21, 2020 - Oct 21, 2020 Role: Principal Investigator |
Genomic and Environmental Determinants of Infant Deaths in San Diego County in 2015-2022 NIH R01HD101540Apr 1, 2020 - Jan 31, 2025 Role: Co-Principal Investigator |
Reassessing FASD: Novel Approaches for Evaluating Exposure, Diagnosis and Outcomes in Children Prenatally Exposed to Alcohol NIH/NIAAA R01AA027785Apr 1, 2020 - Mar 31, 2023 Role: Co-Investigator Description: Using data from the NIH funded Collaboration to Establish the Prevalence and Characteristics of FASD in U.S. Communities (CoFASP), this study aims to examine the characterizations of prenatal alcohol exposure and diagnosis of fetal alcohol spectrum disorders. |
4/6 Planning for the HEALthy Early Development Study NIH R34DA050341Sep 1, 2019 - Mar 31, 2021 Role: Principal Investigator |
The Safety of Asthma Medications During Pregnancy and Lactation: Evidence Gaps and How to Fill Them NIH R13HL149440Sep 1, 2019 - Aug 31, 2020 Role: Principal Investigator |
Detection of Marijuana Metabolites in Breast Milk and Relation to Child Neurodevelopmental Outcomes The Gerber Foundation 6488Jun 25, 2019 - Jun 24, 2022 Role: Co-Principal Investigator |
Prucalopride Pregnancy Exposure Study: a VAMPSS post-marketing surveillance study of Prucalopride safety in pregnancy Takeda Pharmaceutical 20193538Jun 1, 2019 - Jun 30, 2025 Role: Principal Investigator Description: The main goal of this project is to evaluate the maternal and fetal risks associated with the use of Prucalopride during pregnancy. |
Sleep in Children with Fetal Alcohol Spectrum Disorders NIH R21AA026697May 1, 2019 - Apr 1, 2021 Role: Subaward PI |
California Birth Defects Monitoring Program California Department of Public Health 18-0665Apr 1, 2019 - Jun 30, 2022 Role: Principal Investigator |
A Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated with Tildrakizumab Sun Pharma Global FZE 20194611Mar 15, 2019 - Sep 14, 2027 Role: Principal Investigator Description: The main goal of this project is to evaluate the maternal and fetal risks associated with the use of Tildrakizumab during pregnancy. |
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants NICHD HHSN-275201000003IOct 30, 2018 - Sep 21, 2020 Role: Sub award PI |
Child Development Resource Center, A Model of Collaborative, Culturally Congruent, Family-focused Care NIH/NIAAA S06GM128073Oct 1, 2018 - Jul 31, 2022 Role: Co-Investigator Description: This study will test a culturally congruent collaborative care framework among American Indian reservation based families in San Diego County to decrease barriers to care, to decrease stress, depression, and mental – health issues among both children with developmental disabilities and their caregivers, and to improve specific child outcomes. |
International Collaboration to Develop Scalable Methods for Early Detection of Neurodevelopmental Disorder Due to Prenatal Alcohol Exposure NIH R01AA026579Sep 1, 2018 - Jun 30, 2023 Role: Principal Investigator |
Early Predictors of FASD in Ukraine (Supplement) NIH/NIAAA 3U01AA014835-S1Sep 1, 2018 - May 31, 2021 Role: Principal Investigator Description: The purpose of this award is to support efforts to build on the existing aims of this longitudinal cohort study in Ukraine, which are focused on earlier identification of children affected by prenatal alcohol exposure, by addressing the potentially important confounder of comorbidity with HIV infection in pregnant women. |
Discovery of Genetic Basis of Fetal Alcohol Spectrum Disorders NIH/NHLBI/NIAAA 1X01 HL145702-01Sep 1, 2018 - Dec 31, 2020 Role: Principal Investigator Description: The main goal of this study is to examine the role of genetic susceptibility for FASD using mother-child paired biological samples previously collected as part of an NIH funded cohort study in Ukraine. |
San Diego Study of Outcomes in Mothers and Infants (the "SOMI Study”) Rady Children’s Inst. for Genomic Medicine MOUMay 1, 2018 - Dec 31, 2020 Role: Principal Investigator Description: The San Diego Study of Outcomes in Mother and Infants (SOMI) will examine a generation's worth of San Diego births ("'2000-2019) to understand relationships between genomic and epigenomic prenatal and postnatal factors and pediatric health outcomes. |
Benralizumab Pregnancy Exposure Study: a VAMPSS postmarketing surveillance study of Benralizumab safety in pregnancy Astrazeneca 20173256Dec 20, 2017 - Dec 20, 2024 Role: Principal Investigator Description: The main goal of this project is to evaluate the maternal and fetal risks associated with the use of Benralizumab during pregnancy. |
Regeneron Pharmaceuticals, Dupilumab Pregnancy Exposure Registry Regeneron 20172136Sep 27, 2017 - Aug 26, 2027 Role: Principal Investigator Description: The main goal of this project is to evaluate the maternal and fetal risks associated with the use of Dupilumab during pregnancy. |
Detection of Marijuana Metabolites in Human Milk Gerber Foundation 4998May 18, 2017 - Dec 31, 2020 Role: Co-Principal Investigator Description: The main goal of this project is to utilize a recently developed valid quantitative assay for cannabinoids (THC, cannabidiol, and cannabinol) to measure the level of exposure to the infant through human milk. We will examine the quantitative assay results relative to maternal report of the timing, frequency and dose of marijuana use preceding the milk collection. Additionally, we will examine selected infant health-related outcomes associated with various levels of cannabinoid exposure via human milk. |
Sarilumab Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Study Sanofi-Aventis 20172956Jan 1, 2017 - Jan 1, 2027 Role: Principal Investigator Description: The main goal of this project is to evaluate the maternal and fetal risks associated with the use of sarilumab during pregnancy. |
Development of Protocol for Repatha® (evolocumab) Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Study Amgen 2179627Oct 3, 2016 - Oct 2, 2021 Role: Principal Investigator Description: The main goal of this project is to evaluate the maternal and fetal risks associated with the use of Repatha during pregnancy |
The Mepolizumab Pregnancy Exposure Study: a VAMPSS post marketing surveillance study of Mepolizumab safety in pregnancy GlaxoSmithKline LLC. 20164835Sep 14, 2016 - Jul 31, 2022 Role: Principal Investigator Description: The main goal of this project is to evaluate the maternal and fetal risks associated with the use of Mepolizumab during pregnancy. |
Vedolizumab Pregnancy Exposure Registry: an OTIS Autoimmune Diseases in Pregnancy Project Takeda 20152059Nov 5, 2015 - Nov 4, 2020 Role: Principal Investigator Description: The main goal of the study is to monitor planned and unplanned pregnancies exposed to vedolizumab and to evaluate the possible teratogenic effect of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal vedolizumab exposure on infant health through one year of age compared to children born to mothers with ulcerative colitis and/or Crohn’s disease who did not use vedolizumab during pregnancy, and children born to mothers without an autoimmune disease. |
San Diego Clinical and Translational Research Institute (CTRI) NIH/NCATS 5UL1TR0001442-04Aug 31, 2015 - Apr 30, 2025 Role: Co-Investigator |
Apremilast Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project Celgene 20143739Sep 25, 2014 - Dec 31, 2023 Role: Principal Investigator Description: The main goal of the study is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the possible teratogenic effect of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health through one year of age. |
Tofacitinib Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project Pfizer 20131407Jun 17, 2013 - Jul 31, 2025 Role: Principal Investigator Description: The main goal of the Tofacitinib Pregnancy Exposure Registry is to follow pregnant women with or without rheumatoid arthritis who have or have not been treated with tofacitinib during pregnancy to evaluate the possible effect of this disease, and or this medication on the pregnancy outcome including child development and growth up to one year of age. |
Stelara® Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project Janssen Biotech Inc. 20132318Jun 1, 2013 - Dec 31, 2025 Role: Principal Investigator Description: The specific aim of this study is to monitor planned and unplanned pregnancies exposed to Stelara® (ustekinumab), to evaluate whether there are any teratogenic effects of this medication in pregnancy outcomes, and to evaluate potential effects of prenatal use of Stelara® exposure on infant health status through one year of age. |
Influence of nutrition on growth and neurodevelopment in children with FASD NIH R01AA021551Sep 10, 2012 - Jun 30, 2017 Role: Principal Investigator |
Cimzia® Pregnancy Exposure Registry – an OTIS Autoimmune Diseases in Pregnancy Project UCB Pharma, Inc. 20113868Feb 13, 2012 - May 12, 2022 Role: Principal Investigator Description: The purpose of the OTIS Autoimmune Diseases in Pregnancy Project, Cimzia® Pregnancy Exposure Registry is to follow pregnant women with or without rheumatoid arthritis or Crohn’s Disease who have or have not been treated with Cimzia® during pregnancy to evaluate the possible effect of these diseases, and or this medication on the pregnancy outcome including child development and growth up to five years of age. |
The Teriflunomide Pregnancy Exposure Registry – an OTIS Autoimmune Diseases in Pregnancy Project Genzyme(Sanofi-Aventis) 20113565Oct 25, 2011 - Oct 1, 2022 Role: Principal Investigator Description: The main goal of this project is to evaluate the fetal risk associated with the use of a new multiple sclerosis drug during pregnancy. |
OTIS Autoimmune Diseases in Pregnancy Project: the Actemra® Pregnancy Registry Hoffman La Roche 20090812Nov 1, 2010 - Dec 31, 2020 Role: Principal Investigator Description: The main goal for this project is to evaluate the fetal risk associated with the use of Actemra® for RA in pregnancy. |
Collaboration to Establish the Prevalence of FASD in San Diego, CA NIH U01AA019879Sep 20, 2010 - Aug 31, 2018 Role: Principal Investigator |
Pregnancy outcomes and asthma medications in pregnancy: a Demonstration Project NIH R18HS018474Sep 30, 2009 - Jul 31, 2015 Role: Principal Investigator |
Early Predictors of FASD in Ukraine NIH/NIAAA 5U01AA014835Sep 30, 2003 - May 31, 2022 Role: Principal Investigator Description: The major goal of this study is to develop a panel of biomarker tests along with a clinical prediction tool that can help improve our ability to identify children with FASD in infancy so they can obtain optimum benefit from early intervention. |
Dysmorphology Research Resource NIH/NIAAA 5U24AA014815Sep 30, 2003 - May 31, 2022 Role: Co-Investigator Description: The major goal of this project is to use telemedicine and face-to-face examinations to identify children affected by prenatal alcohol exposure in all consortium sites, including remote, medically underserved areas in Minnesota and New Mexico, and to provide these individuals with access to affective intervention programs. |
General Clinical Research Center NIH M01RR000827Mar 1, 1974 - Nov 30, 2010 Role: Co-Investigator |